苏州蚂蚁淘生物科技有限公司成立于2017年，致力于将全球领先的创新产品和前沿技术带入中国，帮助国内科研工作者在第一时间接触世界范围内的技术革命，并分享研发工具的进步带来的技术红利。依托于集团公司深厚的资源和超过400家的国内优质客户群体，生命科学领域的一站式供应链体系，以及高风险生物危险材料进出口平台的优势，蚂蚁淘生物严格筛选国际创新且经过同行验证过的产品和技术，引入中国市场，开发、孵育和推广。公司的未来将立足于实验室大数据整合和电子商务，结合严格的品牌筛选、创新的营销模式、专注的应用支持和坚实服务，帮助实现生命科学产业链的简单和高效。

Vitatex可以将CAM捕获的iCTC分离到高纯度，以便与NGS，PCR或基因表达谱相结合来发现耐药靶标。 

纯iCTC可用于疾病进展的分子分析，包括表明对癌症药物具有药代动力学反应的基因突变和表达水平，以及对转移细胞具有特异性且无毒作用的新药物的新型靶标。

测试仪

血液中CTC的上皮/肿瘤（KRT，EpCAM，MUC16 / CA125，CD24，Tert），祖细胞/ EMT /浸润（CD44v6，TWIST1，seprase）和内皮（CD31，CDH5，VEGFR）基因的表达。

Vitatex的ICTC耐药性（CDR）测试

改善癌症药物选择。

通过Applied DNA方法捕获的iCTC可以存活，并且可以在存在多种癌症药物的情况下轻松培养，以优化针对每个患者的治疗选择。确定哪种癌症药物或药物混合物最有可能使患者受益的能力满足了一项主要需求，而目前可用的方法仅具有有限的解决能力。当前针对该应用程序的有限测试是针对原发性肿瘤，而不是通过Applied DNA技术从血液样本中分离出的与转移相关的iCTC。

CAM具有侵入性和转移性，可捕获活的肿瘤细胞-启用iCTC耐药性（CDR）治疗选择测定。

• 在使用特定疗法治疗患者之前，先测量血液中iCTC和免疫细胞的治疗反应。

• 帮助临床医生为个别患者决定最佳的个性化治疗。

Vitatex is focused on advance personalized medicine with tests of invasive circulating tumor cells (iCTCs) that provide better information about the metastatic potential of a patient’s cancer to improve treatment and reduce health care costs. The company’s unique advantage stems from its patented approach that captures iCTCs directly linked to the metastatic process.

Leveraging its functional Cell Adhesion Matrix (CAM) technology, Vitatex is developing proprietary diagnostic tests that can be run on blood samples, collected by standard current methods, to improve cancer treatment decisions and select effective therapies for recurrence and metastatic diseases.

Improved Cancer Drug Selection: iCTCs captured by the Vitatex method are alive and can readily be cultured in the presence of panels of cancer drugs to optimize selection of treatment tailored to each patient. The ability to determine which cancer drug or drug cocktail is most likely to benefit a patient meets a major need which currently available methods have had only limited ability to address.

Better Prognostic Information: CAM-captured iCTCs can be sorted and counted by automated flow cytometry to provide an early indication of metastasis in pre-operative patients, as well as early detection of recurrence in patients under therapeutic treatment. This greatly improved prognostic information can help the physician decide on aggressive chemo- therapy or other strategies more rapidly and confidently.

Convenient and Effective Treatment Monitoring: Serial measurement of iCTCs in routinely collected patient blood samples during the course of treatment and beyond can monitor for effective response, relapse to allow a timely change of a failing therapy, or to reinitiate therapy following recurrence.

The company’s technology also creates significant opportunities for research products and services that advance development of new cancer drugs and novel cancer markers, as well as support metastasis research. Companies developing new cancer drugs can access new models of metastasis and assay services that improve patient selection and monitoring in clinical trials. Vitatex has also developed proprietary metastatic cell lines and protein markers of invasiveness, including Seprase and DPP4, which strengthen the company’s testing methods and have potential cancer drug development applications.

Vitatex has translated its patented CAM iCTC technology platform into a pipeline of promising innovative diagnostic tests that have entered clinical studies, and into enabling new research products and services. The company is pursuing these opportunities both through its own initiatives and through partnerships being developed with major diagnostic and research tool and service companies

苏州蚂蚁淘生物科技有限公司专注于为科研工作者提供CST，Abcam，Sigma，biorbyt，Abclonal，AbD Serotec，GeneTex，ENZO，ScienCell，BI，Swant，emfret，Biovision，Roche，Millipore，BD，Life，eBioscience，Thermo，Qiagen，Santa，Peprotech，R&D，ImmunoStar，GenStar，GeneCopoeia，Cusabio，Bioss，NeoBioscience